source
- Pembrolizumab with BCG shows 92% 6-month complete response in very high-risk T1 bladder cancerA clinical study evaluated the combination of pembrolizumab and bacillus Calmette-Guérin (BCG) in patients with very high-risk T1 non-muscle invasive bladder cancer who had not previously received…
- Detalimogene Voraplasmid Achieves 54% Complete Response in BCG-Unresponsive Bladder CancerA clinical study of detalimogene voraplasmid reported a 54% complete response rate in patients with heavily pretreated, BCG‑unresponsive non‑muscle‑invasive bladder cancer that also had carcinoma i…